MindWalk Holdings Corp. Q3 2026 Earnings Call Summary

Moby Intelligence

Thu, March 12, 2026 astatine 11:44 AM CDT 3 min read

• Achieved a 3rd consecutive 4th of year-over-year gross growth, driven by a deliberate strategical pivot toward the high-demand U.S. AI-driven find market.

• Signed the archetypal one-year endeavor Lens AI level contract, transitioning the concern exemplary from one-off task fees to predictable, monthly recurring revenue.

• Differentiated the Lens AI level by focusing connected the 'invariant functional layer' of biology (HIFT) alternatively than aboveground series similarity, allowing for the detection of IP risks and functional adjacencies competitors miss.

• Validated the HIFT attack by identifying a azygous conserved functional diagnostic crossed implicit 2,000 influenza sequences, representing a imaginable people for a cosmopolitan immunogen.

• Advanced the dengue programme by targeting a azygous conserved epitope contiguous successful each 4 serotypes, aiming to lick the humanities 'antibody-dependent enhancement' nonaccomplishment mode of erstwhile vaccines.

• Launched the B Cell LAMA level to lick the 'chain-pairing problem' successful multispecific antibody improvement by utilizing people matured llama nanobodies that deficiency airy chains.

• Divested European operations to ore superior and resources connected North American commercialized maturation and Canadian laboratory capabilities.

• Anticipating near-term information readouts for dengue, GLP-1, and influenza programs, with dengue binding confirmation expected wrong the existent week.

• Designing structured asset-level financing vehicles with ineligible and fiscal advisers to money objective advancement portion preserving genitor institution equity.

• Rolling retired the Lens AI portal to a broader basal of astir 750 progressive clients to person existing fee-for-service relationships into SaaS subscriptions.

• Advancing a dual-regimen GLP-1 programme that links weight-loss biology to a non-overlapping longevity pathway based connected pharma collaborator feedback.

• Projecting G&A expenses to stay level oregon amusement humble growth, arsenic existent infrastructure is deemed capable to enactment scaling operations.

• Reported a important simplification successful nett nonaccomplishment to $3.9 cardinal compared to $22 cardinal successful the anterior year, which was impacted by a $21.2 cardinal impairment charge.

• Maintained a currency presumption of $14.2 cardinal to money ongoing R&D and commercialized enlargement successful the Boston-Cambridge biotech hub.

• Published peer-reviewed probe successful Biomacromolecules demonstrating that function-based enactment provides 10 to 25 times greater potency than accepted affinity-based selection.

• Initiated IP extortion for 'functional adjacency' capabilities, a caller competitory moat for identifying molecules with akin effects but debased series similarity.